AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03320460 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: Patients will be treated with localized PBM with a diode laser with continuous wave (laser λ = 660 nm; power 100mW;radiant energy: 177J/cm2; 5-s exposure time per point and 0.5J of energy per point) applied directly to the surrounding oral mucosa and to the center of OLP, always by the same operator, twice a week for 4 weeks, totaling 8 session. The number of points will be variable according to the lesion size. The output power of the laser equipment will be evaluated using a power meter (Laser Check; MMOptics LTDA, São Paulo, Brazil) before treatment to confirm the effective mean power as well as the doses applied during the procedure.
Study NCT03320460 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo gel
Description: Placebo gel for 30 consecutive days to mask the treatment
Study NCT03320460 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Photobiomodulation
Description: Laser device will be positioned over the lesion but will be switched off to mask the treatment.
Study NCT01340911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SRT3025
Description: SRT3025 will be supplied as hard gelatin capsules containing either 27.4 mg (25 mg SRT3025 free base equivalent) or 274 mg (250 mg SRT3025 free base equivalent) of SRT3025 HCl monohydrate drug substance.
Study NCT01340911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: For placebo product, the SRT3025 drug substance will be replaced by Microcrystalline Cellulose (Avicel® PH 105) to match the SRT3025 investigational product.
Study NCT03636035 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tregocel®
Description: Coated tablet (oral)
Study NCT03694457 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reversed total shoulder arthroplasty
Description: Replacement of the proximal humeral head by a reversed prosthesis through an anterior approach
Study NCT03694457 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: lateral approach
Description: Replacement of the proximal humeral head by a reversed prosthesis through a lateral approach
Study NCT01630343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol tablet and Tramadol capsule
Description: Panadol 500mg tablet Q4H prn Tramadol 50mg capsule Q4H prn
Study NCT01630343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panadol 500mg tablet, tramadol 50mg capsule
Description: Regular Panadol 500mg tds with tramadol 50mg capsule tds for 3 weeks after injury
Study NCT02244099 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled Substance
Description: Patients will be identified using the reporting workbench in the EMR if they have been prescribed a controlled substance, carisoprodol, or tramadol at least 3 times in the last 6 months by one of the consenting resident physicians from Martha Morehouse General Internal Medicine Resident Continuity Clinic. Once identified, a comprehensive chart review for other important parameters based on best practice recommendations as described in the research protocol will be conducted in order to characterize the patient population for which the recommendations are being made to the physicians. Improvement in controlled substance, carisoprodol, and tramadol prescribing and adherence to the CSTA by the resident physicians will be tracked using a pre/post intervention comparison.
Study NCT03387514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSMA-based 18F-DCFPyL PET tracer for PET/CT exams
Description: 18F-DCFPyL whole body PET/CT scan administered at the following timepoints:~PET1 - Prior to scheduled nephrectomy~PET2 - to establish a new baseline PET before systemic therapy~* PET2A - Post-surgery and prior to start of standard of care systemic therapy~* PET2B - 12-16 weeks from start of first line systemic therapy (immune-based or anti-angiogenic)~PET3 - If first line systemic therapy did not include anti-angiogenesis therapy and new systemic therapy does include anti-angiogenesis therapy~* PET3A - Prior to start of additional anti-angiogenesis therapy~* PET3B - 12-16 weeks from the start of additional anti-angiogenesis therapy~PET4 - obtained at clinical progression or 2 years following initial systemic therapy
Study NCT03136835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maternal Hyperoxygenation
Description: Oxygen via nasal prongs at up to 4L/min continuously during 2nd and 3rd trimester of pregnancy until birth
Study NCT01954524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV bolus injection of Sildenafil
Description: Dose escalation will be performed (in different participants). The doses will be as follows:~CTP class B cirrhosis: A single 5 and 10 mg IV bolus injections of Sildenafil. CTP class C cirrhosis: A single 2.5, 5, 8 and 10 mg IV bolus injections of Sildenafil.
Study NCT03607903 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab ID
Description: Adalimumab intradermal using MicronJet600 microneedle from NanoPass
Study NCT03607903 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab SC
Description: Adalimumab subcutaneous using regular needle
Study NCT03607903 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline ID
Description: Saline intradermal using MicronJet600 microneedle from NanoPass
Study NCT03607903 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline SC
Description: Saline subcutaneous using regular needle
Study NCT00554333 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flu-ID 15μg
Description: Inactivated Split-Virion Influenza Vaccine for Intradermal Route
Study NCT00554333 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated adjuvanted Influenza Vaccine
Description: Inactivated adjuvanted Influenza Vaccine for Intramuscular Route
Study NCT01159535 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Based Relapse Prevention
Description: The MBRP intervention comprises 8 weekly, 2-hour sessions delivered in small group format (10-14 participants) by two therapists (Bowen, et al., 2009). In MBRP, therapists facilitate discussions and exercises and introduce the meditation practice component.Group sessions include discussions of mindfulness as a means of coping with craving and painful cognitions/sensations that precipitate relapse, role-playing exercises, meditation practice, and homework assignments.
Study NCT01159535 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relapse Prevention
Description: intervention is composed of 8 weekly 2-hour sessions delivered in small group format (10-14 participants)
Study NCT01159535 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: All participants will be enrolled in continuing care services (including attendance at AA, NA, or other self-help groups) as recommended by their treatment providers. Thus, TAU participants will have ongoing support and monitoring by their continuing care providers on a regular basis.
Study NCT03461250 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: HCV serology
Description: Apply CRF to identify risk factors for HCV infection. In patients with positive HCV serology measure the level of viral load and HCV genotype by PCR Abbott-real time and determine the stage of liver fibrosis by elastography (Fibroscan)
Study NCT01740011 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Study NCT01740011 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic surgery
Study NCT01443975 — intervention group
Intervention type: PROCEDURE
Intervention: x-pander
Description: Measurement of the size and quality of the bony acetabulum before mounting the artificial hip socket.
Study NCT03799679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapeutic Agent
Description: Drug: Nanoparticle Albumin-Bound Paclitaxel Nanoparticle Albumin-Bound Paclitaxel 125mg/m2, iv, d1. Patients will receive this as a single-agent for the first twelve weeks, then followed by epirubicin in combination with cyclophosphamide.~Drug: Epirubicin 90 mg/m² given IV~Drug: Cyclophosphamide 600 mg/m² given IV
Study NCT04156152 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DEENSIBILIZING TOOTHPASTE BASED ON NANOCRISTALS OF HYDROXIAPATITA / 5% POTASSIC NITRATE / SODIUM MONOFluORPHOSPHATE 1450 PARTS PER MILLION
Description: The toothpastes will be delivered by the researchers and will be applied with a manual toothbrush, with soft bristles and straight handle, by the patient.The 2nd, 3rd, 4th session (2nd, 4th, 6th week of follow-up) will be the application of tests and reinforcement of oral hygiene instruction. In the 5th session (8th week of follow-up) the pastes will be requested to verify compliance.
Study NCT04156152 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 5% POTASSIC NITRATE / SODIUM FLUORIDE 1426 PARTS PER MILLION TOOTHPASTE
Description: The toothpastes will be delivered by the researchers and will be applied with a manual toothbrush, with soft bristles and straight handle, by the patient.The 2nd, 3rd, 4th session (2nd, 4th, 6th week of follow-up) will be the application of tests and reinforcement of oral hygiene instruction. In the 5th session (8th week of follow-up) the pastes will be requested to verify compliance.
Study NCT04278430 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Description: The tDCS stimulator (ActivaDose II tDCS Device; IOMED Inc., Salt Lake City, USA) is a standardized instrument used and tested in children. Two tDCS electrodes of dimensions 3 x 3 were used for the brain stimulation. The electrodes were inserted into a wet saline sponge.
Study NCT04278430 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: The tDCS stimulator (ActivaDose II tDCS Device; IOMED Inc., Salt Lake City, USA) is a standardized instrument used and tested in children. Two tDCS electrodes of dimensions 3 x 3 were used for the brain stimulation. The electrodes were inserted into a wet saline sponge.
Study NCT04278430 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Five children with LSIH were randomly allocated to this group. All participants received sham tDCS for 3 weeks on alternate days and completed 10 treatment sessions. The sham tDCS followed preparatory procedures similar to that used for the experimental group, except that the device was disconnected after the initial increase of the current. Children usually started the activity without noticing that the device was disconnected. The children were assessed at baseline, during the 5th and 10th sessions, and during a follow-up that was scheduled for 4 months later.
Study NCT01213173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Succinate Metoprolol (Betaloc ZOK®)
Description: treatment with 47.5mg for two weeks, if tolerated and without Systolic blood pressure\<100mmHg and heart rate \<45 bpm according to 12-lead Electrocardiogram at Week 3, the dosage will be titrated to 95mg and last for another 6 weeks
Study NCT01213173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Succinate Metoprolol (Betaloc ZOK®)
Description: Treatment with 95mg for two weeks, and if tolerated and without bradycardia symptoms presented, Systolic blood pressure\<100mmHg and heart rate \<45 bpm according to 12-lead Electrocardiogram at Week 3，the dosage will be force titrated to 190mg and last for another 6 weeks
Study NCT00012181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given IV
Study NCT01156649 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PAP therapy
Description: Nightly use of automatic positive airway pressure delivered at therapeutic levels and to be delivered through a nasal interface device selected to maximize comfort for each child.
Study NCT01156649 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham PAP therapy
Description: During sleep, the sham PAP device will administer a constant pressure of subtherapeutic air (approximately 1 cm of water) through a custom fit nasal interface chosen for the child's maximum comfort.
Study NCT02351908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stribild® (Tenofovir Disoproxil Fumarate, Elvitegravir, Cobicistat)
Study NCT02351908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isentress® (Raltegravir 400 mg)1 tablet twice a day + Truvada® (FTC & Tenofovir) 1 tablet
Study NCT02351908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivicay® (Dolutegravir 50 mg) 1 tablet once a day + Truvada® (FTC & Tenofovir)
Study NCT03889470 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NTG 1 MG/ML Injectable Solution
Description: administered after sheath placement
Study NCT03889470 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NTG 1 MG/ML Injectable Solution
Description: administered after sheath placement
Study NCT00012181 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT02377713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK6640
Description: Single ascending dose administration
Study NCT02377713 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single ascending dose administration
Study NCT04088474 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vigiis 101-LAB
Description: examined the effects of the Vigiis 101-LAB capsules (5 billion CFU/day)
Study NCT04088474 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin was used as a placebo
Study NCT01354106 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Skin Trauma
Description: Each participant completed received both treatment arms, the 3M Micropore and 3M Kind Removal Silicone Tape.
Study NCT01354106 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Skin Trauma
Description: Each participant completed received both treatment arms, the 3M Micropore and 3M Kind Removal Silicone Tape.
Study NCT01803841 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transradial coronary angiography and intervention
Study NCT01803841 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transfemoral coronary angiography and intervention
Study NCT03972774 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PET Stress Test
Description: Cardiac positron emission tomography (PET)/computed tomography (CT) and test-result dependent management
Study NCT03972774 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Non-PET Medical Management
Description: Appropriate medical management without cardiac PET stress-imaging
Study NCT00451841 — intervention group
Intervention type: DEVICE
Intervention: RTube Exhaled Breath Condensate Collection System
Description: Subjects breath through the device to collect exhaled breath condensate
Study NCT03073460 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ultrasound examination
Description: This exam is performed at 40 weeks gestation
Study NCT05595421 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Description: See detail in arm/group descriptions regarding the intervention.
Study NCT03837613 — intervention group
Intervention type: PROCEDURE
Intervention: tumor resection and neck dissection
Description: Surgical removal of the tumor with adequate safety margins. In addition to neck dissection to dissect the cervical lymph nodes.
Study NCT00976703 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: weighted bag
Description: For the weighted bag, a 500cc saline bag will be taped to an empty Foley bag which will be attached to the cervical Foley catheter. This bag will then be placed to gravity over the end of the bed. The bed will be raised so that the bag does not touch the floor. The foley and the bag will be re-assessed every 30min by the nursing staff.
Study NCT00976703 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: leg taping
Description: For the leg taping, the cervical foley catheter will be pulled to gentle traction and attached to the patient's inner thigh using a reclosable foley catheter fastener. The foley catheter and the traction will be assessed every 30min by the nursing staff. The tension will be renewed and the Foley re-adjusted if necessary at each check.
Study NCT04722861 — intervention group
Intervention type: OTHER
Intervention: GVFQ-40
Description: GVFQ-40 is a 40-item questionnaire developed to evaluate the visual ability of glaucoma patients in detail. It consists of 40 items and measures the impact of glaucoma on restriction of participation in daily activities in five domains of functioning. Each item is rated on a five-level scale from ''no difficulty'' to ''can't do because of vision''. Another possible response is that the activity is not performed for nonvisual reasons.
Study NCT00975221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Description: Administered orally at a starting dose of 30 mg twice a day (BID). Participants will be eligible for a dose titration once every 3 weeks during the placebo-controlled dose titration phase based on corrected total serum calcium concentration and safety assessments obtained the previous week. Doses may be sequentially increased to 60 mg BID, 90 mg BID, and 90 mg 3 times a day (TID).
Study NCT00975221 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cinacalcet
Description: Administered orally at a starting dose of 30 mg twice a day (BID). Participants will be eligible for a dose titration once every 3 weeks during the placebo-controlled dose titration phase based on corrected total serum calcium concentration and safety assessments obtained the previous week. Doses may be sequentially increased to 60 mg BID, 90 mg BID, and 90 mg 3 times a day (TID).
Study NCT00975221 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally following the same tiitration regimen as the experimental arm.
Study NCT02818660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Synachten
Description: To stimulate the adrenals to increase the cortisol Production as much as possible
Study NCT03139838 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EHR-Based Intervention A
Description: Intervention A will be a prompt for clinicians to document an estimated prognosis for patients at 6 months, and an assessment of predicted functional outcome if expected to survive.
Study NCT01364441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-2952
Description: 3 mg to 800 mg at a single dose; 10 mg and 200 mg for food effect study
Study NCT03139838 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EHR-Based Intervention B
Description: Intervention B will entail a prompt for clinicians to provide a reason for not offering patients and their families the alternative of care focused entirely on comfort despite recommendations from critical care professional societies to do so for patients at high risk for death or severely impaired functional recovery.
Study NCT02351440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duloxetine
Description: patients will be randomized to receive either duloxetine or placebo
Study NCT02351440 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT01364441 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo dosed in the same manner as ONO-2952
Study NCT05654558 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auxiliary cantilever intrusion arches on initial archwires
Description: Patients received a full set of 0.022- inch slot brackets (Mini 2000, Ormco) with Roth prescription. Lower first molars received double tubed bands while 2nd molars received single bondable tubes. Leveling and alignment phase then started with 0.014 inch NiTi wires engaging all teeth and synched behind 2nd molars. Two 0.017 x 0.025 TMA (Ormco) sectional wires were attached to auxiliary tubes on 1st molars with tip back bends mesial to the molars and attached with hooks distal to lateral incisors on top of basal leveling arch wire. Amount of intrusive force was measured to range between 20 and 40 grams per side. Basal leveling arches were upgraded whenever needed. All patients were assessed after 6 months of treatment.
Study NCT05654558 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Routine leveling and alignment
Description: Patients received a full set of 0.022- inch slot brackets (Mini 2000, Ormco) with Roth prescription, 1st and 2nd molars received tubes or bands according to each patient's further needs Lower arch was leveled and aligned with sequential wires starting with 14 NiTi and upgraded when needed. All patients were assessed after 6 months of treatment.
Study NCT04275180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Argatroban
Description: Argatroban plus standard medical treatment
Study NCT03063970 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Lycra Orthosis
Description: Dynamic lycra orthoses: made to measure fabric lycra compression gauntlets individually tailored to correct upper limb movement and positioning. Worn for eight hours per day but may be removed for therapy and washing.
Study NCT03063970 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Rehabilitation
Description: Physiotherapy or Occupational Therapy delivered as routine part of rehabilitation
Study NCT00694564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-adenosyl methionine
Description: S-adenosyl methionine will be dosed as 200 mg tablets with doses ranging from 200 to 1400 mg daily.